An orthogonally protected CycloTriVeratrylene (CTV) as a highly preorganized molecular scaffold for subsequent ligation of different cyclic peptides towards protein mimics.
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Introduction
Protein mimics form a category of medium sized molecules, which might have a large impact because they could become viable medium-sized molecule alternatives of biologics such as antibodies and vaccines. Thus, they may have advantages closer to those of smaller molecules such as better bio-availability and stability and be less immunogenic. We have provided bases for realization of molecular construction of protein mimics by (1) the development of syntheses of different scaffolds for attachment of (cyclic) peptides, [1] [2] [3] [4] (2) synthetic approaches for attachment of different (cyclic) peptides to scaffolds, [5] [6] [7] [8] [9] [10] and (3) the generation of collections of the resulting protein mimics. 9, 11, 12 The latter aspect is especially note worthy since design of an optimal protein mimic is often hardly possible even when a significant amount of structural data is available, so there has to be a versatile approach to prepare collections or libraries of protein mimics, which can be screened to find protein mimic "hits" 9, 12 For this purpose a non-orthogonally protected scaffold is used, providing direct access to the required unprotected protein mimics, which can be screened as mixtures or as single compounds, followed by MS-identification of the hit(s). 11, 12 However, this/these hit(s) then have to be re-synthesized using the an orthogonally protected scaffold to obtain appreciable quantities of single protein mimic compounds for validation of the hit and subsequent structural and biological activity studies Thus, a scalable (re)synthesis approach for any individual hit is absolutely essential. So far, we have developed semiorthogonally protected TAC, ATAC and TACO scaffolds, 1, 3, 4 Figure 1. Orthogonally protected TAC 1, 3, 13, 14 , ATAC 3 , and TACO 4 scaffolds which can be applied for the convenient synthesis of selected protein mimics (Figure 1 ). Other important orthogonally protected molecular scaffolds include the RAFT-peptide (Mutter and co-workers 15 ), cholic acid derivatives (Savage and coworkers 16 ), cyclic β-peptide and penta-erythrityltetramine derivatives (Lönnberg and co-workers 17, 18 ), a pentaerythritol derivative (De Clerq and co-workers 19 ) as well as a cyclicpeptide derivative by Eichler and co-workers. 20 The synthesis of a (semi)orthogonally protected CycloTriVeratrilene (CTV) scaffold derivative as well as the sequential introduction of three different peptide loops onto this molecular scaffold via Cu(I)-catalyzed azide alkyne cycloaddition towards a medium-sized protein mimic is described. This approach for the construction of medium-sized protein mimics is illustrated by the synthesis of a paratope mimic of the monoclonal antibody Infliximab (Remicade ® ) and provides access to a range of highly pre-organised molecular constructs bearing three different peptide segments. This approach may find wide applications for development of protein-protein interaction disruptors as well as synthetic vaccines. In the past we have used the highly pre-organized CycloTriVeratrylene (CTV) scaffold successfully for development of effective collagen mimics. 2 More recently, preparation of collections of gp120 protein mimics, using these different scaffolds, showed that CTV-scaffolded gp120 epitope mimics were the most powerful protein mimics (IC50-values of the gp120-CD4 interaction in ELISA of 1.7 and 2.2 μM). 12 Therefore, we felt it was necessary to develop an orthogonally protected CTV derivative, so that the selected protein mimics can be re-synthesized. In this research we describe the synthesis of the highly pre-organized semi-orthogonally protected CTV scaffold as well as an example of sequential introduction of three different cyclic peptides towards individual protein mimics.
Results and discussion
Similar to the recently described semi-orthogonal alkyne functionalized TAC-scaffold 1 (Figure 2 ), we wished to develop a semi-orthogonally alkyne functionalized CTV scaffold 2. However, in contrast to the TAC-scaffold, 1,3 1 orthogonality of protection cannot be achieved during synthesis of the CTV scaffold 21 6 (Scheme 1) itself, but has to be introduced postsynthesis, thus, after completion of its synthesis. First, it was attempted to mono-functionalize the CTV scaffold 6 with propargyl bromide (14) . This gave only low yields of CTV propargyl ether 7, together with di-alkylated derivative 8 and starting material, which were hardly separable. Therefore, it was attempted to temporarily protect two phenolic hydroxy functionalities and subsequently alkylate the remaining free hydroxy group. Attempts to protect two hydroxy functionalities as bis-esters or bis-silylethers were unsuccessful. Nevertheless, the desired temporary protection was achieved using THP protecting group, which afforded the desired di-THP derivative 9 from CTV 6 under mild conditions in a decent 30% yield (Scheme 2). Moreover, the di-THP derivative 9 was easily separable from mono and tri-THP-ethers 10, which could then be converted back to CTV 6 in a moderate yield. Subsequently, di-THP ether 9 was alkylated to give 11 followed by removal of the THP-protecting group leading to mono-propargyl ether 7 in a good (70% over 2 steps) yield. Scheme 2. Synthesis of mono-propargyl CTV 7 via di-THP-CTV ether 9
Next, silyl protected alkynes were introduced onto the mono alkylated scaffold 7 (Scheme 3). Since the TIPS-group is more stable, alkyne bromide 21 was introduced first onto the propargyl CTV derivative 7.
Along with the desired mono-TIPS derivative 12 the di-TIPS side product 13 was formed. Because of the formation side product 13 and only 1.05 eq. of 21 used in the reaction, some starting material 7 remained unreacted and was recovered (25%). Finally, the mono-TIPS derivative 12 was alkylated with TES-protected alkyne bromide 15 to give the desired semi-orthogonally protected CTV scaffold derivative 2 in a good yield (72%) (Scheme 3). The preparation of the required silyl protected alkyne bromides 15 and 21 is shown in Scheme 4. First, a direct silylation of propargyl bromide 14 with TES-Cl was attempted (Scheme 4). However, the target TES-protected alkyne bromide 15 was obtained in a low yield partly due to formation of the substitution by-product 16. Here too, the THP group offered a remedy. Hence, the desired silyl protected alkyne bromides 15 and 21 were prepared starting from propargyl alcohol 17 which was protected as a THP ether 18. Following the protection, the free alkyne of the THP ether 18 was silylated with either TES-Cl or TIPS-Cl to give corresponding TES and TIPS protected analogues 19 and 20 respectively. Lastly, bromination and concomitant removal of the THP ethers of the silyl protected alkynes 19 and 20 led to the formation of the desired silyl protected alkyne bromides 15 and 21.
To illustrate the potential of the semi-orthogonally protected CTV scaffold 2 for the construction of protein mimics, three cyclized peptides obtained by using our recently described polar hinge 10 , were sequentially introduced in a convenient "click and cleavage" approach. The peptide segments represent CDR-loops of the monoclonal antibody Infliximab (Remicade ® ), which is a powerful tumor necrosis factor α (TNF α) inhibitor. The amino acid sequences of these peptides were derived from the X-ray structure of an Infliximab-TNFα-trimer complex 22 After their solid phase syntheses, the N,C-terminal dicysteine containing peptides were cleaved and deprotected, followed by chemoselective cyclization using polar hinge 22 leading to cyclic peptides 26-28 (Scheme 5). The azide functionality in the hinge 22 allowed ligation of the resulting cyclic peptides by Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC) onto the CTV scaffold derivative 2 in a similar manner as was described previously for semi-orthogonally protected TAC scaffold 1. 13, 14 However, no microwave irradiation was necessary and the solvent mixture was changed to i-PrOH/DMF/H2O 4/3/1, v/v/v for complete dissolution of the CTV scaffold derivative 2. Thus, first cyclic peptide 26 was ligated to 2 via CuAAC to give the CTV scaffold containing one peptide loop (29) , in a good yield (70%) (Scheme 5). Next, the TES protecting group was mildly removed using AgNO3 leading to deprotected scaffold derivative 30 (68%) and cyclic peptide 27 was ligated via CuAAC to afford the CTV scaffold containing two peptide loops i.e. 31 (40%). The last peptide loop 28 was introduced by CuAAC after removal of the TIPS protecting group (TBAF·3H2O in DMF, 42%) to complete the molecular construction of the three peptide loops containing protein mimic 33 of Infliximab in 40% yield.
Conclusion
We have described the construction of an orthogonally protected molecular scaffold, which is probably the most preorganized scaffold presently available for the construction of protein mimics. Moreover, owing to the protection group strategy desired different peptide segments can be introduced corresponding to different epitopes, paratopes, protein hot-spots etc., which offers a great potential for applications of this CTV scaffold including antibody mimics and synthetic vaccines.
In this research we have described a versatile construction of a mimic (33) of the anti-TNFα monoclonal antibody Infliximab (Remicade ® ) containing three different cyclic peptides
2) TES-Cl or TIPS-Cl -78°C=>RT corresponding to three CDR-loops of this antibody. These cyclic peptides were introduced in "click and cleavage" approach, in which sequentially a peptide loop was ligated, followed by cleavage of the protecting group and repeating this procedure. In establishing this procedure the mono and dipeptide loop constructs were purified and characterized, but we think that this procedure has possibilities for a fast and easy preparation of protein mimics in a "kit-like" manner with only purification after the last stage.
19:
Under present investigation is the biological evaluation of the obtained bio-molecular construct. Although a strong biological activity is of course hoped for, realistically, probably libraries of this antibody mimic have to be prepared first, before finding hits with decent biological activities. However, this will be possible using our earlier described combinatorial approach for obtaining collections of discontinuous epitopes 11 , now to be applied to the paratope of Infliximab. Promising hits can then be re-synthesized for validation and on a larger scale using the orthogonally protected CTV scaffold described here.
Finally, it is important to realize that also other (bio) molecular constructs e.g. different carbohydrate constructs, nucleic acid can be selectivity ligated to this semi-orthogonally protected CTV scaffold, which may open up a plethora of applications.
Experimental part

General information
All reagents and solvents were used as received.
1 H NMR and the 13 C NMR spectra were recorded on Bruker 400 MHz Spectrospin spectrometer (400 MHz, 100 MHz) in CDCl3. Chemical shifts (δ) are reported in parts per million (ppm) relative to trimethylsilane (TMS, 0.00 ppm) or CDCl3 (7.26 ppm). Splitting patterns are designated as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m). TLC was carried out on silica gel plates (Merck 60F254) and the visualization was performed by both, the UV detection (254 nm) and staining solutions (cerium molybdenate, potassium permanganate) followed by heating. For column chromatography, silica gel Geduran ® Si 60 (40 -63 μm) was used. All chemicals and solvents were purchased from regular commercial sources in analytical or HPLC grade and were not further purified. Dry solvents (THF, DCM) were dispensed from Pure Solv™ 500 Solvent Purification System and other dry solvents (acetonitrile) were prepared from commercially available HPLC grade solvents by removal of residual water with 4Å molecular sieves overnight. HRMS-ESI was recorded on Bruker microTOFq High Resolution Mass Spectrometer in a positive mode. EI-MS was recorded on Jeol MSTATION JMS-700 in a positive mode.
Fmoc-amino acids were obtained from Activotec (Cambridge, United Kingdom) and N,N,N′,N′-Tetramethyl-O-(6-chloro-1H-benzotriazol-1-yl)uranium hexafluorophosphate (HCTU) was obtained from Matrix Innovation (Quebec, Canada). Tentagel S RAM resin (particle size 90μm, capacity 0.25 mmol.g -1 ) was obtained from IRIS Biotech (Marktredwitz, Germany). Methyl tert-butyl ether (MTBE), n-hexane (HPLC grade) and TFA were obtained from Aldrich (Milwaukee, USA). DMF (Peptide grade) was obtained from VWR (Lutterworth, United Kingdom). Piperidine and DiPEA were obtained from AGTC Bioproducts (Hessle, United Kingdom), and 1,2-ethanedithiol (EDT) was obtained from Merck (Darmstadt, Germany). HPLC grade CH2Cl2 and acetonitrile were obtained from Fischer Scientific (Loughborough, United Kingdom). Solid phase peptide synthesis was performed on a PTI Tribute-UV peptide synthesizer.
Lyophilizations were performed on a Christ Alpha 2-4 LDplus apparatus. Analytical high pressure liquid chromatography (HPLC) was carried out on a Shimadzu instrument comprising a communication module (CBM-20A), autosampler (SIL-20HT), pump modules (LC-20AT), UV/Vis detector (SPD-20A) and system controller (Labsolutions V5.54 SP), with a Phenomenex Gemini C18 column (110 Å, 5 μm, 250 × 4.60 mm). UV measurements were recorded at 214 and 254 nm, using a standard protocol: 100% buffer A (acetonitrile/H2O 5:95 with 0.1% TFA) for 2 min followed by a linear gradient of buffer B (acetonitrile/H2O 95:5 with 0.1% TFA) into buffer A (0-100%) over 30 min at a flow rate of 1.0 mL·min -1 . Purification of peptidic compounds was performed on an Agilent Technologies 1260 infinity preparative system using UV detector with a Phenomenex Gemini C18 column (110 Å, 10 μm, 250 × 20 mm). Auto-collection of fractions was based on the UV measurements at 214 nm, using either 100% buffer A or 95% buffer A with 5% buffer B for 5 min followed by and linear gradient of buffer B into buffer A (specified for each compound) over 65 min at a flow rate of 12.5 mL·min -1 using the same buffers as described for analytical HPLC. Liquid chromatography mass spectrometry (LCMS) was carried out on a Thermo Scientific LCQ Fleet quadrupole mass spectrometer with a Dionex Ultimate 3000 LC using a Dr. Maisch Reprosil Gold 120 C18 column (110 Å, 3 μm, 150 × 4.0 mm), using a 0-100% linear gradient of buffer B into buffer A and the same flow rate and buffers as described for analytical HPLC.
Scaffold synthesis and derivatization
1-O-allyl-vanillyl alcohol (4)
Compound 4 was prepared according to a modified literature procedure. 21 To the solution of vanillyl alcohol 3 (55.0 g, 356.8 mmol) in acetone (82 mL), K2CO3 (49.8 g, 360.3 mmol) and allyl bromide (34.0 mL, 392.5 mmol) were added. The resulting mixture was stirred under reflux for 4.5 h. Afterwards, acetone was removed under reduced pressure and the residue was partioned between CH2Cl2 (500 mL) and water (400 mL). The organic phase was then dried over MgSO4, and filtered. Crude 4 (65.1 g, 94.0%) was obtained upon removal of CH2Cl2 under reduced pressure. The crude product was crystallized from MTBE/n-hexane affording 4 (60.3 g, 87.0%) as white crystals. Rf = 0.32 (n-hexane/EtOAc 6/4). 1 21 in the following manner. Compound 4 (57.4 g, 295.5 mmol) was dissolved in MeOH (340 mL) and the solution was cooled to 0°C resulting in the formation of a precipitate. Next, upon the dropwise addition of 60% (aq) HClO4 (171 mL) the precipitate dissolved and the solution became pink. Once HClO4 was added, the reaction mixture was allowed to warm up to RT and stirred for 16.5 h during which white precipitate gradually formed. Afterwards, the reaction mixture was diluted with CH2Cl2 (570 mL) and washed with water (7 × 570 mL) till the neutral pH was reached, which can be also recognized by the change of the color of the organic layer from pink to yellow. The organic phase was then dried over MgSO4, filtered, concentrated under reduced pressure to give pale yellow solid which was suspended in Et2O (100 mL) and stirred for 2 h before being filtered off. The filtrate was washed with Et2O CTV-triOH (6) Compound 6 was prepared according to a modified literature procedure. 21 To the solution of 5 (26.0 g, 49.2 mmol) in dioxane/EtOH (130 mL/230 mL), 10% Pd/C (5.4 g), 65% (aq) HClO4 (5.4 mL) were added and the resulting reaction mixture was stirred under nitrogen atmosphere at 65°C for 24 h and then for 48 h at RT. Next, catalyst was filtered off and washed with dioxane (50 mL) and CH2Cl2 (200 mL). The filtrate was then washed with water (2 × 700 mL, 2 × 500 mL), aqueous layer was extracted with CH2Cl2 (100 mL) and the combined organic layer was dried over MgSO4, filtered, concentrated under reduced pressure to ca 100 mL, and allowed to crystallize. The crystals were filtered off, washed with cold CH2Cl2 (3 × 30 mL) and dried on a high vacuum to afford 6 (10.5 g, 52.1%) as white crystals. Rf = 0.18 (n-hexane/EtOAc 1/1 
Di(O-THP) CTV-OH (9), Mono(O-THP) CTV-diOH and Tri(O-THP) CTV (10)
To a suspension of CTV 6 (5.0 g, 12.4 mmol) in CHCl3 (124 mL), DHP (2.3 mL, 25.4 mmol) and p-TsOH monohydrate (0.02 g, 0.1 mmol) were added. After 2 h of stirring, during which the reaction mixture became pink, additional DHP (1.2 mL, 12.3 mmol) was added, which resulted in the formation of a solution which was stirred for an additional 1 h. Afterwards, the reaction mixture was diluted with Et2O (125 mL) followed by immediate addition of saturated NaHCO3 (50 mL). Direct addition of CHCl3 or saturated NaHCO3 to reaction mixture was attempted too but lead to partial decomposition in certain cases. Next, the aqueous layer was extracted with Et2O (100 mL) and the combined organic layer was dried over MgSO4, filtered, and solvents were removed under reduced pressure. The crude product was purified by a column chromatography (n-hexane/EtOAc 2. 13 (m, 3H) . Rf = 0.52 (n-hexane/EtOAc 1/1).
Recovery of CTV-triOH (6)
To the suspension of side products 10 in MeOH (13 mL per 1 g of mixture), 1M HCl (2.6 mL per 1 g of mixture) was added and the reaction mixture was stirred for 2 h during which a white precipitate was formed. Afterwards, MeOH was removed under reduced pressure and the creamy residue was dissolved in EtOAc/MeOH (40/1, v/v, 130 mL per 1 g of mixture) and washed with water/brine (1/1, v/v, 40 mL per 1 g of mixture). The aqueous layer was extracted with EtOAc (25 mL per 1 g of mixture) and the combined organic layer was washed with brine (25 mL per 1 g of mixture), dried over MgSO4, filtered, and concentrated under reduced pressure to a low volume. White precipitate was formed during removal of solvents. The suspension was kept at +4°C overnight before the white precipitate was filtered off and washed with EtOAc to give compound 6 ( typically between 58% -74%).
Di(O-THP)-O-propargyl CTV (11)
To the solution of compound 9 (1.0 g, 1.7 mmol) in acetonitrile (17 mL) Cs2CO3 (0.6 g, 1.9 mmol) was added, followed by the addition of propargyl bromide (80% in toluene) (0.23 mL, 2.1 mmol) and the resulting reaction mixture was stirred for 2.5 h. Afterwards, acetonitrile was removed under reduced pressure and the viscous residue was diluted with EtOAc (100 mL) and washed with water (100 mL). Aqueous layer was extracted with EtOAc (50 mL) and combined organic layer was washed with brine (50 mL), dried over MgSO4, filtered, and EtOAc was removed under reduced pressure. The crude product was purified by a column chromatography (n-hexane/EtOAc 9/1 to n-hexane/EtOAc 7/3). Compound 11 (0.8 g, 76.8%) was obtained as a white foam. Rf = 0.51 (n-hexane/EtOAc 1/1). 1 
O-Propargyl CTV-diOH (7)
Compound 11 (790 mg, 1.29 mmol) was suspended in MeOH (20 mL) and then 1M HCl (1 mL) was added. The reaction mixture was stirred for 1 h during which the suspension turned into a yellow solution. Afterwards, MeOH was removed under reduced pressure and the viscous residue was diluted with EtOAc (40 mL) and washed with water (30 mL). Next, the aqueous phase was extracted with EtOAc (20 mL) and the combined organic layer was washed with brine (30 mL), dried over MgSO4, filtered, and EtOAc was removed under reduced pressure. The crude product was purified by a column chromatography (CHCl3 to CHCl3/MeOH 50/1).
Compound 7 (524 mg, 91.4%) was obtained as a white foam. Rf = 0.25 (n-hexane/EtOAc 1/1 
O-Propargyl-O-(TIPS)propargyl CTV-OH (12), O-Propargyl bis[O-(TIPS)propargyl] CTV (13)
Cs2CO3 (181 mg, 0.56 mmol) was added to the solution of compound 7 (226 mg, 0.51 mmol) in dry acetonitrile (20 mL). Next, a solution of compound 21 (146 mg, 0.53 mmol) in dry acetonitrile (3 mL) was added dropwise. The reaction mixture was stirred under nitrogen atmosphere for 20 h. Afterwards, acetonitrile was removed under reduced pressure and the residue was suspended in Et2O (40 mL) and washed with 1M KHSO4 (40 mL). The aqueous layer was extracted with Et2O (20 mL) and the combined organic layer washed with brine (40 mL), dried over MgSO4, filtered, and Et2O was removed under reduced pressure. The crude product was purified by a column chromatography (CH2Cl2 to CH2Cl2/MeOH 100/1) to afford compound 13 (93 mg, 23.2%) as a pale yellow solid. Rf = 0.87 (n-hexane/EtOAc 1/1). 1 
O-Propargyl-O-(TIPS)propargyl-O-(TES)propargyl CTV (2)
To the suspension of compound 12 (303 mg, 0.47 mmol) in dry acetonitrile (5 mL) Cs2CO3 (162 mg, 0.50 mmol) was added followed by the addition of the solution of compound 15 (121 mg, 0.52 mmol) in dry acetonitrile (0.5 mL). The resulting mixture was stirred for 5.5 h and then acetonitrile was removed under reduced pressure. The viscous residue was suspended in Et2O (40 mL) and washed with water (30 mL). The aqueous layer was extracted with Et2O (30 mL) and the combined organic layer washed with brine (20 mL), dried over MgSO4, filtered, and Et2O was removed under reduced pressure. The crude product was purified by a column chromatography (n-hexane/Et2O 3/1 to nhexane/Et2O 2/1). Compound 2 (269 mg, 71.7%) was obtained as a white foam. Rf = 0.60 (n-hexane/EtOAc 3/1). 1 
Preparation of silyl alkyne bromides O-THP Propargyl alcohol (18)
Compound 18 was prepared according to a literature procedure. 24 To the solution of propargyl alcohol 17 (2.6 mL, 44.6 mmol) and p-TsOH monohydrate (0.09 g, 0.5 mmol) in CH2Cl2 (45 mL) DHP (4.3 mL, 46.8 mmol) was added dropwise at 0°C. After stirring for 5 min at 0°C, the reaction mixture was allowed to warm up to RT and was stirred for 1 h. Next, the reaction mixture was washed with saturated NaHCO3 (30 mL) and the aqueous layer was extracted with CH2Cl2 (45 mL). The combined organic layer dried over MgSO4, filtered, and concentrated under reduced pressure to give compound 18 (6.1 g, 97.2%) as a yellow oil. Rf = 0.30 (n-hexane/Et2O 95/5). (20) Compound 20 was prepared according to a modified literature procedure. 26 A solution of compound 18 (1.0 g, 7.1 mmol) in dry THF (20 mL) was cooled to -78°C. Next, n-BuLi (3.0 mL, 7.5 mmol, 2.5M in hexane) was added dropwise and the reaction mixture was stirred under nitrogen atmosphere at -78°C for 1 h before TIPS-Cl (1.7 mL, 7.9 mmol) was added. The reaction mixture was then allowed to warm up to RT and stirred under nitrogen atmosphere for additional 4 h before it was quenched by addition of saturated NH4Cl (15 mL). The reaction mixture was extracted with Et2O (2 × 25 mL), dried over MgSO4, filtered, and Et2O was carefully removed under reduced pressure with water bath kept at RT. The crude product was purified by a column chromatography (n-hexane to n-hexane/Et2O 99/1) to afford 20 (1. 26 Br2 (130 μL, 2.53 mmol) was added dropwise at 0°C to a solution of Ph3P (697 mg, 2.66 mmol) in dry CH2Cl2 (10 mL) and the solution was stirred under nitrogen atmosphere for 30 min during which a white precipitate was formed. Next, compound 20 (750 mg, 2.53 mmol) was added dropwise and the reaction mixture was stirred under nitrogen atmosphere at 0°C for additional 5 h during which the white precipitate dissolved. The reaction mixture was then diluted with water (15 mL) and extracted with n-hexane (2 × 20 mL). The combined organic layer was washed with saturated NaHCO3 (10 mL), dried over MgSO4, filtered, and n-hexane was carefully removed under reduced pressure with water bath kept at RT. The crude product was purified by a column chromatography using (n-hexane) to afford 21 (682 mg, 98.0%) as a clear oil. Rf = 0.69 (n-hexane).
O-THP (TIPS)Propargyl alcohol
1 H NMR (400 MHz, CDCl3): δ = 1.07 (m, 21H), 3.95 (s, 2H). 13 C NMR (100 MHz, CDCl3): δ = 11.2, 15.0, 18.5, 89.2, 101.9. This compound has been also previously reported. 27 27 A solution of compound 18 (1.0 g, 7.1 mmol) in dry THF (20 mL) was cooled to -78°C. Next, n-BuLi (3.0 mL, 7.5 mmol, 2.5M in hexane) was added dropwise and the reaction mixture was stirred under nitrogen atmosphere at -78°C for 1 h before TES-Cl (1.3 mL, 7.9 mmol) was added. The reaction mixture was then allowed to warm up to RT and stirred under nitrogen atmosphere for additional 4 h before it was quenched by addition of saturated NH4Cl (15 mL). The reaction mixture was extracted with Et2O (2 × 25 mL), dried over MgSO4, filtered, and Et2O was carefully removed under reduced pressure with water bath kept at RT. The crude product was purified by a column chromatography using (n-hexane to n-hexane/Et2O 99/1) to afford 19 (1.6 g, 87.9%) as a clear oil. Rf = 0.42 (n-hexane/Et2O 95/5). 1 26 Br2 (0.3 mL, 5.9 mmol) was added dropwise at 0°C to a solution of Ph3P (1.6 g, 6.2 mmol) in dry CH2Cl2 (23.6 mL) and the solution was stirred under nitrogen atmosphere for 30 min during which a white precipitate was formed. Next, compound 19 (1.5 g, 5.9 mmol) was added dropwise and the reaction mixture was stirred under nitrogen atmosphere at 0°C for additional 5 h during which the white precipitate dissolved. The reaction mixture was then diluted with water (15 mL) and extracted with n-hexane (2 × 20 mL). The combined organic layer was washed with saturated NaHCO3 (10 mL), dried over MgSO4, filtered, and n-hexane was carefully removed under reduced pressure with water bath kept at RT. The crude product was purified by a column chromatography using (n-hexane) to afford 15 (1.1 g, 82.3%) as a clear oil. Rf = 0.66 (n-hexane).
O-THP (TES)Propargyl alcohol (19)
1 H NMR (400 MHz, CDCl3): δ = 0.61 (q, J = 7.9 Hz, 6H), 0.99 (t, J = 7.8 Hz, 9H), 3.95 (s, 2H). 13 C NMR (100 MHz, CDCl3): δ = 4.2, 7.3, 14.8, 90.1, 101.2. This compound has been also previously reported. 29 
Peptide synthesis and preparation of synthetic antibody
. . 1 . L i n ea r p ep t i d es
General method for automated peptide synthesis: The peptides were synthesized on a PTI Tribute-UV peptide synthesizer. Tentagel S RAM resin (1.0 g, 0.25 mmol, 1.0 equiv or 400 mg, 0.1 mmol, 1.0 equiv) was allowed to swell (3 x 10 min). Deprotection of the Fmoc group was achieved by treatment of the resin with 20% piperidine in DMF using the RV_top_UV_Xtend protocol from the Tribute-UV peptide synthesizer followed by a DMF washing step (5 x 30 sec). The Fmoc-protected amino acids (with the 0.1 mmol scale 5 equiv was used and with the 0.25 mmol scale 4 equiv was used) were coupled using HCTU (with the 0.1 mmol scale 5 equiv was used and with the 0.25 mmol scale 4 equiv was used) and DiPEA (with the 0.1 mmol scale 10 equiv was used and with the 0.25 mmol scale 8 equiv was used) in DMF, as a coupling system, with 2 min pre-activation. The coupling time was 10 min when the peptide was synthesized on a 0.1 mmol scale and 20 min when the 0.25 mmol scale was conducted. After every coupling the resin was washed with DMF (6 x 30 sec). After the last amino acid coupling, the Fmoc group was cleaved using the normal deprotection conditions (described above) and the resulting free N-terminus was acetylated by treatment of the resin bound peptide with acetic anhydride (250 μL) and DiPEA (10 equiv for the 0.1 mmol scale and 8 equiv for the 0.25 mmol scale) in DMF using the standard coupling times (described above). After the last step the resin was washed with DMF (5 x 30 sec), DCM (5 x 30 sec), dried over a nitrogen flow for 10 min, followed by the cleavage of the resin-bounded peptide. Cleavage and global deprotection was achieved by treatment of the resin with TFA/H2O/TIS/EDT (10 mL for the 0.25 mmol scale and 5 mL for the 0.1 mmol scale, 90/5/2.5/2.5, v/v/v/v) for 3 hours. Next, the peptide was precipitated by dropwise addition of the TFA mixture to a cold (4 °C) solution of MTBE/n-hexane (1/1, 90 mL for the 0.25 mmol scale and 45 mL for the 0.1 mmol scale). After centrifugation (3500 rpm, 5 min) the supernatant was decanted and the pellet was re-suspended in MTBE/n-hexane (1/1, v/v) and centrifuged again. Finally, the pellet was washed twice with MTBE/n-hexane 50 mL ( 
. . 2 . C ycl i c p ep t i d es
All linear peptides were cyclized at the concentration of 1 mM in the following way. The crude linear peptide and the perhydro triazine hinge 22 were placed into a flask. Then, acetonitrile was added followed by the addition of aqueous solution of NH4HCO3 (20 mM, pH = 7.9) to form a 1/3 (acetonitrile/NH4HCO3 v/v) mixture. The progress of the cyclization was checked by analytical HPLC after 30 min. In case of all the peptides, 30 min were sufficient for the complete cyclization. Next, acetonitrile was removed under reduced pressure and the remaining aqueous solution/suspension was lyophilized. The crude cyclic peptides were purified using preparative HPLC. The fractions containing product were combined and lyophilized yielding the desired cyclic peptides as a white fluffy solid.
Cyclic peptide·2TFA (26) 
. . 3 . Pr ep a r a t i o n o f a s yn t h et i c a n t i b o d y mi mi c
CTV Scaffold derivative (29) 
CTV Scaffold derivative (30)
To a solution of scaffold derivative 29·2TFA (10.3 mg, 4.53 μmol) in degassed DMF (680 μL), degassed i-PrOH (910 μL), and deionized H2O (225 μL), AgNO3 (3.9 mg, 22.65 μmol) was added and the reaction mixture was stirred under nitrogen atmosphere and monitored by analytical HPLC which showed complete conversion after 1 h. Then, the solvents were removed with nitrogen stream giving clear honey which was diluted with buffer A (1300 μL). The resulting solution was centrifuged (4500 rpm, 5 min) and purified using 5% to 100% of buffer B in buffer A. Scaffold derivative 30·2TFA (6.3 mg, 64.3%) was obtained as a white fluffy solid after lyophilization. tR = 24.9 min and 25.1 min (diastereoisomers). LCMS-ESI: average mass calcd [M+2H] 2+ : 965.7; found: 965.5.
CTV Scaffold derivative (31)
Scaffold derivative 30·2TFA (6.0 mg, 2.78 μmol), cyclic peptide 27 (4.3 mg, 3.06 μmol), TBTA (0.4 mg, 0.83 μmol) were placed into a flask and degassed DMF (415 μL) was added and the mixture was stirred under nitrogen atmosphere until clear solution was obtained. Next, degassed i-PrOH (555 μL), deionized H2O (125 μL) were added followed by the addition of 0.2M aqueous sodium ascorbate (8.4 μL, 1.67 μmol) and 0.12M aqueous CuSO4 (7.0 μL, 0.83 μmol). The reaction mixture was stirred under nitrogen atmosphere and monitored by analytical HPLC which showed complete conversion after 19 h. Then, the solvents were removed with nitrogen stream giving red thick solid which was diluted with buffer B (50 μL) and buffer A (470 μL). The resulting solution was centrifuged (4500 rpm, 5 min) and purified using 5% to 90% of buffer B in buffer A. Scaffold derivative 31·3TFA (4.0 mg, 40.4%) was obtained as a white fluffy solid after lyophilization. tR = 21. were added followed by the addition of 0.2M aqueous sodium ascorbate (2.5 μL, 0.49 μmol) and 0.12M aqueous CuSO4 (2.1 μL, 0.25 μmol). The reaction mixture was stirred under nitrogen atmosphere and monitored by analytical HPLC which showed complete conversion after 89 h. Then, the solvents were removed with nitrogen stream giving red solid which was diluted with buffer B (50 μL) and buffer A (460 μL). The resulting solution was centrifuged (4500 rpm, 5 min) and purified using 5% to 80% of buffer B in buffer A. Synthetic antibody 33·5TFA (0. 8 
